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Abstract 
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterised by motor 
and non-motor symptoms, resulting from the degeneration of nigrostriatal dopaminergic 
neurons and peripheral autonomic neurons. Given the limited success of neurotrophic factors 
in clinical trials, there is a need to identify new small molecule drugs and drug targets to 
develop novel therapeutic strategies to protect all neurons that degenerate in PD.  
 Epigenetic dysregulation has been implicated in neurodegenerative disorders, while 
targeting histone acetylation is a promising therapeutic avenue for PD. We and others have 
demonstrated that histone deacetylase inhibitors have neurotrophic effects in experimental 
models of PD. Activators of histone acetyltransferases (HAT) provide an alternative approach 
for the selective activation of gene expression, however little is known about the potential of 
HAT activators as drug therapies for PD.  
To explore this potential, the present study investigated the neurotrophic effects of 
CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide), which is a 
potent small molecule activator of the histone acetyltransferase p300/CBP, in the SH-SY5Y 
neuronal cell line. We report that CTPB promoted the survival and neurite growth of the SH-
SY5Y cells, and also protected these cells from cell death induced by the neurotoxin 6-
hydroxydopamine. This study is the first to investigate the phenotypic effects of the HAT 
activator CTPB, and to demonstrate that p300/CBP HAT activation has neurotrophic effects 
in a cellular model of PD. 
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Abbreviations 
6-OHDA - 6-hydroxydopamine 
BMP - bone morphogenetic protein(s) 
CTPB - N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide 
DA – dopaminergic/dopamine  
DAPI - 4'-6-diamidino-2-phenylindole 
DMSO - dimethyl sulfoxide 
DIV – day(s) in vitro 
H3- total histone H3 
HAT - histone acetyltransferase(s) 
HDAC - histone deacetylase(s) 
LDH - lactate dehydrogenase  
MTT - Thiazolyl Blue Tetrazolium Bromide 
N - number of repetitions 
pAcH3 - p-acetylated-histone H3 
PBS-T - 10mM PBS containing 0.02% Triton X-100 
PD - Parkinson’s disease 
SNpc - substantia nigra pars compacta 
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Introduction   
Parkinson’s disease (PD) is a chronic neurodegenerative disease that is second only to 
Alzheimer’s disease in its worldwide prevalence. It affects 1-2% of people over the age of 65, 
and this incidence significantly increases with age (Dorsey et al. 2013). PD is a motor 
disorder, with many accompanying non-motor symptoms (Jankovic 2008; Lees et al. 2009). 
PD is characterised by the progressive loss of midbrain dopaminergic (DA) neurons in the 
substantia nigra pars compacta (SNpc) resulting in reduced DA neurotransmission in the 
striatum, leading to motor dysfunction. A second defining feature of PD is the presence of 
intraneuronal Lewy body inclusions, consisting of predominantly α-synuclein that are found 
throughout the central, peripheral, and autonomic nervous systems (CNS, PNS and ANS) 
(Bethlem and Den Hartog Jager 1960; Jellinger 1991; Jellinger 2012). In parallel to the 
striatal DA denervation (Bedard et al. 2011), there is also heterogeneous peripheral 
denervation (Goldstein et al. 1997; Goldstein et al. 2000; Kaufmann and Goldstein 2013), 
with the most common being sympathetic denervation of the left ventricular myocardium 
leading to orthostatic hypotension (Lucio et al. 2013). One of the most promising disease-
modifying therapies for PD involves the delivery of neurotrophic factors to the striatum 
and/or SNpc to protect DA neurons (Hegarty et al. 2014b). While this is a promising 
approach, it has had limited success to date in clinical trials (Olanow et al. 2015). In addition, 
such localised administration of neurotrophic factor ligands is unlikely to protect other 
neurons that are affected by the disease process. Therefore, while neurotrophic factors remain 
a promising therapeutic approach for protecting DA neurons, it is important to identify new 
drugs, and drug targets, that may be useful in protecting all neurons affected by PD.  
 It is increasingly recognized that epigenetic dysregulation plays a key role in disorders 
of the nervous system (Abel and Zukin 2008; Chuang et al. 2009; Hahnen et al. 2008; Hodges 
et al. 2006; Jiang et al. 2008; Kazantsev and Thompson 2008; Saha and Pahan 2006). One 
key epigenetic process is histone acetylation which controls the ease with which transcription 
factors can access DNA to regulate gene expression (Allfrey et al. 1964; Serrano et al. 2013). 
Histone acetylation involves a dynamic interplay between two classes of enzymes, known as 
histone acetyltransferases (HAT) and histone deacetylases (HDAC), that respectively control 
histone acetylation and deacetylation (Yang and Seto 2007). We and others have shown that 
pan- and class-specific HDAC inhibitors can protect DA neurons (Chen et al. 2006; Chen et 
al. 2007; Collins et al. 2015; Gardian et al. 2004; Kidd and Schneider 2010; Kidd and 
Schneider 2011; Kontopoulos et al. 2006; Outeiro et al. 2007; St Laurent et al. 2013; Wu et 
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al. 2008; Zhu et al. 2014) and sympathetic neurons (Collins et al. 2015) in experimental 
models of PD. The potential of this approach for clinical translation is highlighted by an on-
going Phase I clinical trial of the FDA-approved drug Glycerol Phenylbutyrate (a HDAC 
inhibitor) which is exploring the potential of this drug to increase the removal of α-synuclein 
from the brain (NCT02046434) (for recent reviews see Harrison and Dexter 2013; Schneider 
et al. 2013; Valor et al. 2013). An alternative epigenetic approach for the broad, yet selective, 
activation of gene expression is the induction of HAT activity, instead of HDAC inhibition. 
However, there is little known about the potential of HAT activators as potential drug 
therapies for PD.  
The global transcriptional co-activator p300/CBP is a potent HAT that plays essential 
roles in nervous system development (Lopez-Atalaya et al. 2014; Sheikh 2014; Tanaka et al. 
2000; Yao et al. 1998). p300/CBP HAT is recruited to DNA by direct interaction with 
specific transcription factors, which enhances transcriptional activity by acetylation of 
histones proximal to the promoter region. Recent reports have shown that peripheral 
administration of carbon nanosphere-conjugated small molecular activators of p300/CBP 
increases histone acetylation in the brain (Chatterjee et al. 2013; Selvi et al. 2008). 
Furthermore, p300/CBP has also been shown to activate bone morphogenetic protein (BMP)-
Smad-mediated transcription (Pearson et al. 1999), which is known to promote the survival 
and growth of midbrain DA (Hegarty et al. 2014a; Hegarty et al. 2013) and sympathetic 
neurons (O'Keeffe et al. 2016). This highlights the potential for targeting p300/CBP as a 
therapeutic approach (Valor et al. 2013) to protect both DA and sympathetic neurons in PD.  
To begin to address this potential, we employed a selective and potent small 
molecular activator of p300/CBP known as CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-
ethoxy-6-pentadecyl-benzamide) (Balasubramanyam et al. 2003). CTPB is a benzamide that 
activates p300/CBP HAT activity but not that of p300/CBP-associated factor (PCAF). CTPB 
enhances p300/CBP HAT-dependent transcriptional activation, and has no effect on histone 
deacetylase activity (Balasubramanyam et al. 2003). The ability of CTPB to selectively 
modulate p300 HAT activity has been further characterised (Devipriya and Kumaradhas 
2013; Devipriya et al. 2010; Mantelingu et al. 2007), exploited to synthesize novel 
p300/CBP-targeting compounds (Souto et al. 2010; Souto et al. 2008), and demonstrated in 
vivo (Selvi et al. 2008). However, there have been no studies investigating the phenotypic 
effects of CTPB-mediated p300/CBP HAT activation in cellular or animal models of PD. 
Herein we provide the first evidence showing that CTPB exerts neurotrophic effects in the 
SH-SY5Y cell line, which is a widely used model of human DA and sympathetic neurons. 
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Materials and Methods 
Cell Culture 
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12 
(Sigma), supplemented with 10% foetal calf serum (Sigma), 100nM L-Glutamine (Sigma), 
100U/ml Penicillin/Streptomycin (Sigma), in a humidified atmosphere containing 5% CO2 at 
37˚C. For neurite growth assays, a plating density of 5×104 cells/well of a 24-well plate was 
used, while viability and death assays had a plating density of 1×10
5
 cells/well in a 24-well 
plate. For western blotting, 2×10
6
 cells were plated per well of a 6-well plate. Where 
indicated, cells were treated with 0.5-200μM of CTPB (Enzo Life Sciences) or a vehicle 
(equivalent % of Dimethyl Sulfoxide (DMSO); Sigma) for 24h or daily for 4 days in vitro 
(DIV). For DMSO controls, cells were treated with % of DMSO equal to highest 
concentration of CTPB within the experiment. For the neurotoxin assays, cells were treated 
with 5-100μM of 6-hydroxydopamine (6-OHDA; Sigma) for 24h. 
 
Immunocytochemistry 
Cultures were fixed in 4% paraformaldehyde in 10mM PBS for 10 min at -20˚C. Following 
three washes in 10mM PBS containing 0.02% Triton X-100 (PBS-T in 10mM PBS) for 
permeabilization, cultures were incubated in blocking solution (5% bovine serum albumin 
(Sigma) in 10mM PBS) for 1h at room temperature. Cultures were subsequently incubated in 
the following primary antibodies: p-acetylated-histone H3 (Ser 11/Lys 15) (pAcH3; 1:200; 
rabbit polyclonal IgG; Santa Cruz) and β-actin (1:200; mouse polyclonal IgG; Sigma) diluted 
in 1% bovine serum albumin in 10mM PBS at 4˚C overnight. Following 3 x 5min washes in 
PBS-T, cells were incubated in Alexa Fluor 488- or 594-conjugated secondary antibodies 
(1:500; Invitrogen) reactive to the species of the primary antibodies and diluted in 1% bovine 
serum albumin in 10mM PBS, at room temperature for 2h in the dark. Cultures were 
counterstained with 4'-6-diamidino-2-phenylindole (DAPI; 1:1000 in 10mM PBS; Sigma). 
Cells were imaged under an Olympus IX70 inverted microscope fitted with an Olympus 
DP70 camera and AnalysisD
TM
 software. The fluorescence intensity of individual cells 
stained for pAcH3 was measured using Image J analysis software (Rasband, WJ, 
http://rsb.info.nih.gov/ij/). The relative fluorescence intensity was calculated as the intensity 
of each individual cell after subtraction of the background noise.  
 
Cell Viability and Cell Death Assessment 
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Thiazolyl Blue Tetrazolium Bromide (MTT) assays were performed to assess cell viability as 
previously described (Hegarty et al. 2013). MTT was added to cells at a concentration of 
0.5mg/ml. To assess cellular toxicity/death, lactate dehydrogenase (LDH) activity was 
measured in 100μl of the cell culture medium of each treatment group using an LDH Activity 
Assay Kit (Sigma), according to the provider’s instructions. Fresh cell culture medium, which 
had no contact with cultured cells, was used as the negative control. 
 
Measurement of Cellular Morphology  
5 microscopic fields were randomly selected for each experiment, and photographed using an 
Olympus IX70 inverted microscope. All cells in each photograph were measured. The length 
of the neuritic arborisation was estimated using standard stereological procedures (Mayhew 
1992). A line grid was superimposed on the microscopic images and the number of times 
each neurite intersected the grid was recorded using Image J analysis software. The neurite 
length was calculated using the following formula: NL = α x T x (π/2), where α is the number 
of times the neurite intersects the grid lines, and T is the distance between the gridlines on the 
magnified image (taking into account the magnification factor).  
 
Western Blotting 
Western blotting was carried out as described (Crampton et al. 2012). Cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer (50μl RIPA per 1×106 cells; 50mM Tris-HCL; 
150mM NaCl, 1% Triton X-100, 1mM EDTA, 1mM NaF, 1mM Na3VO4, 1μg/ml leupeptin 
and 1μg/ml pepstatin) for 1h on ice, and insoluble debris was removed by centrifugation. 
15μg of protein was run by SDS-PAGE and transferred to nitrocellulose membranes using a 
Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, CA, USA). The membranes were 
incubated with primary antibodies against pAcH3 (1:1000), total histone H3 (H3; rabbit 
polyclonal IgG; Abcam) or β-actin (1:2000) overnight at 4°C, washed, incubated with the 
appropriate goat IR700/800-labelled secondary antibodies (1:10000; Licor), washed and 
visualised with Odyssey (Licor). Protein levels were normalised to β-actin by densitometry 
using Image Studio Lite software (Licor). 
 
Statistical Analysis 
Unpaired Student’s t-test or one-way ANOVA with a post hoc Tukey’s test was performed, 
as appropriate, to determine significant differences between groups. Results were expressed 
as means with SEM and deemed significant when p<0.05. 
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Results 
A dose-response analysis of CTPB in SH-SY5Y cells. 
To determine a viable working concentration of the small molecular activator of p300/CBP 
HAT, CTPB, in the SH-SY5Y neuronal cell line, these cells were treated with increasing 
concentrations of CTPB ranging from 0.5-200μM. An MTT assay, which is often used to 
measure cell viability by measuring cellular respiration through mitochondrial activity, 
showed that CTPB concentrations above 100μM caused non-selective SH-SY5Y cell death 
after 1DIV (data not shown). At 4DIV, daily treatments with CTPB concentrations of 50μM, 
100μM or 200μM significantly decreased MTT absorbance compared to control (Fig. 1A). 
Examination of phase contrast images indicated that there was cell death at these higher doses 
(Fig. 1B), which accounted for the reduction in cellular viability (Fig. 1A). To confirm that 
DMSO was not toxic, SH-SY5Y cells were cultured in 0.2% or 0.4% DMSO (equivalent 
concentration of DMSO to that in 100μM or 200μM of CTPB, respectively) for 4DIV. 
DMSO at any concentrations tested had no significant effect on cell viability (Fig. 1A). At 
CTPB concentrations of 10μM and below, SH-SY5Y cell viability was not adversely affected 
by daily CTPB treatments for up to 4DIV (Fig. 1A-B). The MTT assay also showed that daily 
treatment with 5μM and 10μM of CTPB significantly increased the MTT absorbance of SH-
SY5Y cells compared to control at 4DIV (Fig. 1A). These data suggest that there is a 
therapeutic range in which CTPB alters the basal state of SH-SY5Y cells. 
 
CTPB promotes neurite growth in SH-SY5Y cells.  
As an increase in MTT absorbance (mitochondrial activity) could indicate increased 
proliferation, decreased cell death or differentiation and neurite growth (Habash et al. 2015; 
Steketee et al. 2012; Tao et al. 2014), we next examined whether targeted activation of 
p300/CBP HAT using CTPB altered the total number of cells, the numbers of pyknotic nuclei 
or neurite growth in SH-SY5Y cells. We used neurite growth as a measure of differentiation 
as class-specific HDAC inhibitors have previously been shown to induce neurite growth of 
SH-SY5Y cells (Collins et al. 2015). Having identified working concentrations of CTPB, SH-
SY5Y cells were treated daily with either control (HBSS or 0.01% DMSO) or 0.5μM, 1.0μM, 
2.5μM or 5μM of CTPB before being immunostained for β-actin at 4DIV, to allow 
visualisation of the cellular cytoskeleton, and counterstained with DAPI. Daily treatment with 
either 2.5μM or 5μM of CTPB resulted in a significant increase in the total neurite length/cell 
of SH-SY5Y cells compared to vehicle-treated control cultures (Fig. 2A-B). However, SH-
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SY5Y cells treated with the lower concentrations of 0.5μM or 1.0μM did not have 
significantly longer neurites when compared to controls (Fig. 2A). In contrast, there were no 
significant differences in the number of pyknotic cells per field (DMSO: 2.1 ± 0.3; CTBP 2.0 
± 0.3) or total cell number per field (DMSO: 149.1 ± 32.0; CTBP 114.7 ± 26.0) in SH-SY5Y 
cells treated with 0.01% DMSO or 5μM of CTPB for 4DIV, suggesting that 5μM of CTPB 
does not affect the numbers of viable or dying SH-SY5Y cells. To explore this further, we 
next determined whether CTBP increased the numbers of neurites and/or the total neurite 
length in individual cells. Daily treatment of SH-SY5Y cells with 5μM of CTPB resulted in a 
significant increase in neurite length of individual SH-SY5Y cells compared to 0.01% 
DMSO-treated controls at 4DIV, but had no effect on the number of primary neurites (Fig. 
2C-D). These findings indicate that CTPB-induced neurite growth in SH-SY5Y cells results 
from increasing the length of existing neurites rather than their number. 
 
6-OHDA neurotoxin dose-dependently induces cell death in SH-SY5Y cells.  
To further examine the neurotrophic potential of CTPB, the ability of CTPB to protect SH-
SY5Y cells against the cell death induced by DA neurotoxin 6-OHDA was next assessed. To 
facilitate such an investigation, a dose-response experiment was initially performed to 
identify a concentration of 6-OHDA which was submaximal (~50%) in its neurotoxic effect. 
SH-SY5Y cells were cultured in increasing concentrations of 6-OHDA (5-100μM) for 24h, 
after which cell viability and cell death were measured by MTT assay and LDH assay, 
respectively. Increasing concentrations of 6-OHDA resulted in a concentration-dependent 
reduction in cell viability, and a corresponding concentration-dependent increase in cell death 
(Fig. 3A-C). Maximal cell death was observed with 6-OHDA concentrations of 25μM and 
above after 24h, while 5μM of 6-OHDA had no significant effect on cell viability or death 
(Fig. 3A-B). A 15μM concentration of 6-OHDA was selected for subsequent 
experimentation, as this concentration induced a ~50% reduction in MTT absorbance (Fig. 
3A) and a ~50% increase in LDH release (Fig. 3B), thus facilitating the examination of any 
neuroprotective effects of CTPB. 
 
CTPB increases histone acetylation in SH-SY5Y cells.  
CTPB is a selective and potent small molecular activator of p300/CBP that has been shown to 
enhance p300/CBP HAT activity in vitro (Balasubramanyam et al. 2003; Devipriya and 
Kumaradhas 2013; Devipriya et al. 2010; Mantelingu et al. 2007) and in vivo when coupled 
to a CSP carrier (Selvi et al. 2008). To determine if CTPB significantly increases p300/CBP 
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HAT activity in this cell line, the levels of acetylated histones were first measured by 
immunocytochemical staining of SH-SY5Y cells for pAcH3 following CTPB treatment. 
Treatment of SH-SY5Y cells with 2.5μM or 5μM of CTPB for 24h induced a significant 
increase in the levels of pAcH3 relative to vehicle-treated counterparts, which was quantified 
by densitometry (Fig. 4A-B). This finding was confirmed by western blot analysis of cells 
treated with 5μM CTPB for 24h. CTPB treatment significantly increased the levels of pAcH3 
relative to total histone H3 protein levels, when compared to control treated SH-SY5Y cells 
(Fig. 4C). This was measured by densitometric quantification of the ratio of pAcH3 to total 
histone H3 protein levels, relative to the β-actin loading control. In addition to this, the effect 
of the 6-OHDA on the levels of acetylated histones was also assessed. Treatment of SH-
SY5Y cells with the submaximal (~50%) neurotoxic dose of 6-OHDA, 15μM, for 24h had no 
effect on the levels of pAcH3/H3 compared to control (Fig. 4C). Furthermore, CTPB or 6-
OHDA treatment did not significantly increase the levels of total histone H3 compared to 
control, despite an increase in total histone H3 levels following CTPB treatment. These data 
indicate that CTPB-induced p300/CBP HAT activation induces hyperacetylation of histone 
H3 in SH-SY5Y cells. 
 
CTPB significantly protects against the cell death induced by neurotoxin 6-OHDA in 
SH-SY5Y cells.  
To further examine the neurotrophic potential of CTPB-induced activation of p300/CBP 
HAT, the ability of CTPB to protect SH-SY5Y cells against the cell death induced by DA 
neurotoxin 6-OHDA was assessed. SH-SY5Y cells were cultured in the presence of 15μM of 
6-OHDA with or without 5μM of CTPB for 24h, at which time MTT and LDH assays were 
performed to measure cell viability and cell death respectively. SH-SY5Y cells treated with 
6-OHDA or 6-OHDA and CTPB, had significantly reduced cell viability and significantly 
increased cell death compared to vehicle-treated controls, as assessed by MTT assay and 
LDH assay (Fig. 5A-C). However, CTPB significantly protected against the cell death 
induced by 6-OHDA in SH-SY5Y cells. CTPB- and 6-OHDA-treated SH-SY5Y cells had 
significantly increased cell viability (Fig. 5A) and significantly decreased cell death (Fig. 5B) 
compared to those treated with 6-OHDA alone. These data have demonstrated that CTPB 
protects SH-SY5Y cells against neurotoxic insult. Taken together with the findings above, 
these results suggest that CTPB-induced p300/CBP HAT activity promotes survival and 
neurite growth in this neuronal cell line. 
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Discussion 
A number of reports have documented neurotrophic effects of HDAC inhibitors in SH-SY5Y 
cells and other cellular models of midbrain DA neurons in vitro (Chen et al. 2006; Chen et al. 
2007; Collins et al. 2015; Gardian et al. 2004; Kidd and Schneider 2010; Kidd and Schneider 
2011; Kontopoulos et al. 2006; Outeiro et al. 2007; St Laurent et al. 2013; Wu et al. 2008; 
Zhu et al. 2014). However, to our knowledge, the present study is the first to show that a 
selective HAT activator can induce similar neurotrophic effects in the SH-SY5Y neuronal 
cell line. SH-SY5Y cells have been used extensively as models of human DA and 
sympathetic neurons (Collins et al. 2015; Hegarty et al. 2013; Toulouse et al. 2012; Xie et al. 
2010) and have been shown to be capable of differentiation into DA-synthesising neurons 
(Gomez-Santos et al. 2002; McMillan et al. 2007; Presgraves et al. 2004; Xie et al. 2010). In 
the present study, we found that CTPB-induced p300/CBP HAT activation promotes the 
survival and neurite growth of SH-SY5Y cells. We also found that CTPB significantly 
increases histone acetylation in these cells, most likely through induction of p300/CBP HAT 
activity. Finally, this study found that CTPB is capable of protecting SH-SY5Y cells from the 
cell death induced by the DA neurotoxin 6-OHDA. This study is the first to investigate the 
phenotypic effects of p300/CBP HAT activation by CTPB, and to demonstrate that small 
molecule-mediated p300/CBP HAT activation has neurotrophic effects in a cellular model of 
PD. 
 In support of our findings, p300/CBP has been shown to contribute to the survival, 
differentiation and neurite growth of a variety of neuronal cell types in the nervous system in 
vitro and in vivo (Chatterjee et al. 2013; Chen et al. 2010; Cong et al. 2005; Culmsee et al. 
2003; Gaub et al. 2011; Gaub et al. 2010; Koyano-Nakagawa et al. 1999; Lee et al. 2009; 
Morikawa et al. 2005; Rouaux et al. 2003; Seo et al. 2012; Sun et al. 2001; Tsui et al. 2014; 
Wang et al. 2010; Wong et al. 2005). In terms of the development of midbrain DA neurons, 
which progressively degenerate in PD, there is evidence to suggest that p300/CBP contributes 
to the acquisition of a DA phenotype in differentiating neurons (Seo et al. 2012). 
Furthermore, in relation to PD-affected peripheral sympathetic neurons, p300/CBP has been 
shown to be an important transcriptional co-activator in the neuronal survival- and 
differentiation-inducing effects of NGF/NF-kappaB signalling (Chen et al. 2010; Culmsee et 
al. 2003; Wong et al. 2005), which are essential regulators of neuronal development in the 
PNS (Davies 2009; Glebova and Ginty 2005; Gutierrez et al. 2005; Gutierrez et al. 2008). In 
addition to this, Hand2 is an important transcription factor for sympathetic nervous system 
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development whose function is dependent on its interaction with p300/CBP (Morikawa et al. 
2005). p300/CBP is also a transcriptional co-activator for BMP-Smad signalling, which is 
known to promote the survival and growth of midbrain DA neurons and sympathetic neurons 
(Hegarty et al. 2014a; Hegarty et al. 2013; O'Keeffe et al. 2016; Pearson et al. 1999). Taken 
these findings together, p300/CBP may act as an important transcriptional co-activator in the 
development, growth and survival of DA and sympathetic neurons, which would make 
p300/CBP HAT a potential therapeutic target for PD. 
 In the present study, following the identification of viable working concentrations of 
CTPB, we initially found that CTPB induced the neurite growth of SH-SY5Y cells. While 
HDAC inhibitors have previously been shown to induce neurite growth in these cells (Collins 
et al. 2015; Yuan et al. 2001), this is the first report documenting the ability of a HAT 
activator to promote SH-SY5Y neurite growth. This is an important finding considering the 
limited number of HAT activators which have been produced (Schneider et al. 2013), and the 
corresponding paucity of studies investigating their neurotrophic potential. The ability of 
p300/CBP activity to promote neurite growth has been reported in other neuronal populations 
(Gaub et al. 2011; Gaub et al. 2010; Lee et al. 2009), while small molecule-mediated 
activation of p300/CBP promotes the growth of neurons in the adult mouse dentate gyrus in 
vivo (Chatterjee et al. 2013).  
 We subsequently confirmed the ability of CTPB to induce hyperacetylation of histone 
H3 in the SH-SY5Y cells, which was most likely due to selective activation of p300/CBP 
HAT activity. Indeed, CTPB has been consistently demonstrated to induce p300/CBP HAT 
activity, in which histone acetylation levels were typically assessed in vitro 
(Balasubramanyam et al. 2003; Devipriya and Kumaradhas 2013; Devipriya et al. 2010; 
Mantelingu et al. 2007) and in vivo when coupled to a CSP carrier (Selvi et al. 2008).  This 
suggests that the CTPB-induced neurotrophic effects observed in this study may be mediated 
by increased p300/CBP HAT activity. Finally, we demonstrated that CTPB significantly 
protects SH-SY5Y neuronal cells against 6-OHDA-induced neurodegeneration. p300/CBP 
HAT activity has previously been shown to promote the survival of a variety of neuronal cell 
types (Culmsee et al. 2003; Rouaux et al. 2003; Wong et al. 2005); however, this is the first 
demonstration that  p300/CBP HAT activity protects against cell death induced by neurotoxin 
6-OHDA. Thus, this study has identified p300/CBP HAT activator CTPB as a promising 
neuroprotective agent with relevance to PD. 
 Given the neurotrophic effects of small molecule HAT activator CTPB reported in 
this study, targeting p300/CBP HAT activity may be a viable neurotrophic strategy. 
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Interestingly, α-synuclein has been reported to reduce p300/CBP expression and HAT 
activity in DA neurons (Jin et al. 2011). Therefore, targeting p300/CBP may be beneficial in 
two ways; firstly through the promotion of neuronal survival and growth, and secondly by 
counteracting the α-synuclein-induced reduction of p300/CBP HAT activity. CTPB is 
potentially a promising molecule for targeted induction of p300/CBP activity in this regard 
(Balasubramanyam et al. 2003), however much more work is needed in translational animals 
models of PD, including exploring strategies to deliever it to the brain. Interestingly, carbon 
nanosphere-conjugated CTPB has the ability to cross the blood-brain-barrier, localize to 
specific nuclei in the brain and induce hyperacetlyation in vivo (Selvi et al. 2008). As such 
these non-toxic, carbon nanospheres-conjugated CTPB small molecules should be 
investigated for their ability to induce neuroprotective effects in 6-OHDA and in particular α-
synuclein animal models of PD. Also the ability of CTPB to act both centrally and 
peripherally in the nervous system also provides a rationale for studying its effects on 
sympathetic axons in vivo.  This is important as the majority of proposed disease-modifying 
therapies for PD to date have focused on midbrain DA neurons, while PNS neurons which 
contribute to debilitating non-motor symptoms are overlooked.  
 Collectively, the above reports in conjunction with our present study suggest that 
HAT activators, such as the small molecule CTPB, provide a promising and exciting area of 
research for neurological disorders. The in vitro findings reported in this study suggest that 
CTPB may be beneficial in PD. CTPB should be examined in animal models of PD as the 
next stage in rationalizing its use as a potential therapy for this disorder. 
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Figures and Figure Legends 
    
Figure 1: A dose-response analysis of CTPB in SH-SY5Y cells.  
(A) Standardised MTT assay of CTPB-treated SH-SY5Y cells when treated daily for 4DIV 
with either control, DMSO (0.2% or 0.4%) or CTPB (0.5-200μM), as indicated (*p<0.05, 
**p<0.01, ***p<0.001 v control; ANOVA with post-hoc Tukey’s test. Number of repetitions 
(N) = 7). (B) Representative photomicrograph of control and CTPB-treated (5μM and 
200μM) SH-SY5Y cells. Scale bar = 100μm. 
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Figure 2: CTPB promotes neurite growth in SH-SY5Y cells.  
(A) Graph showing the total neurite length per cell when treated daily for 4DIV with either 
control, DMSO (0.01%) or CTPB (0.5-5μM), as indicated (*p<0.05, **p<0.01 v control; 
One-way ANOVA with post-hoc Tukey’s test; 20 images analysed per group per experiment. 
N = 3). (B) Representative photomicrographs of SH-SY5Y cells grown in control or CTPB 
(2.5μM and 5μM) and immuocytochemically stained for β-actin and counterstained with 
DAPI at 4DIV. Scale bar = 100μm. Graph showing the individual cell neurite length (C) or 
number of primary neurites (D) of SH-SY5Y cells treated daily for 4DIV with either DMSO 
(0.01%) or CTPB (5μM), as indicated (***p<0.001 v control; Unpaired student t-test; 20 
cells per group. N = 3).  
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Figure 3: Concentration-dependent effect of 6-OHDA on cell death in SHSY5Y cells.  
(A) Standardised MTT assay and (B) LDH assay of SH-SY5Y cells treated with increasing 
concentrations of 6-OHDA (5-100μM) for 24h (**p<0.01, ***p<0.001 v control; One-way 
ANOVA with post-hoc Tukey’s test; N = 6). (C) Representative photomicrographs of control 
and CTPB-treated (10μM and 200μM) SH-SY5Y cells after 24h. Scale bar = 100μm.  
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Figure 4: CTPB increases histone acetylation in SH-SY5Y cells.  
(A) Graph showing the relative immunofluorescence intensity of acetylated histones (pAcH3) 
in SH-SY5Y cells treated for 24h with either control, DMSO (0.01%) or CTPB (2.5-5μM), as 
indicated (**p<0.01, ***p<0.001 v control; One-way ANOVA with post-hoc Tukey’s test; 
50 cells analysed per group per experiment. N = 3). (B) Representative photomicrographs of 
control and CTPB (5μM)-treated SH-SY5Y cells and immunocytochemically stained for 
pAcH3 after 24h. Scale bar = 100μm. (C) Western blotting showing pAcH3 and total histone 
H3 protein levels in SH-SY5Y cells treated for 24h with control, CTPB (5μM) or 6-OHDA 
(15μM). β-actin was used as a loading control. Graph showing densitometric quantification of 
the ratio of pAcH3 to total histone H3 protein levels, relative to β-actin levels (*p<0.05 v 
control; Unpaired student t-test; N = 3).  
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Figure 5: CTPB significantly protects against the cell death induced by neurotoxin 6-
OHDA in SH-SY5Y cells. 
(A) Standardised MTT assay and (B) LDH assay on SH-SY5Y cells treated with 15μM 6-
OHDA in the presence or absence of 5μM CTPB for 24h (*p<0.01, ***p<0.001 v control; + 
p<0.05 v 6-OHDA alone; One-way ANOVA with post-hoc Tukey’s test; N = 6). (C) 
Representative photomicrographs of control, 6-OHDA (15μM) and/or CTPB (5μM)-treated 
SH-SY5Y cells at 24h. Scale bar = 100μm. 
 
 
 
 
 
 
